Graft-vs.-host disease

Critical Reviews in Oral Biology and Medicine

Volumn 8, Issue 2, 1997, Pages 201-216

  Woo, Sook Bin ^a   Lee, Stephanie Joi ^a   Schubert, Mark M ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

oral findings; review; treatment; ulcers; xerostomia

Indexed keywords

ANESTHETIC AGENT; BETAMETHASONE; BICARBONATE; CLOBETASOL; CYCLOSPORIN; DEXAMETHASONE; DYCLONINE; FLUOCINONIDE; IMMUNOSUPPRESSIVE AGENT; LIDOCAINE; STEROID; TRIAMCINOLONE ACETONIDE; VALERIC ACID;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW DEPRESSION; CLINICAL EXAMINATION; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOMA; MOUTH LESION; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0030996768     PISSN: 10454411     EISSN: None     Source Type: Journal    
DOI: 10.1177/10454411970080020701     Document Type: Article

References (137)

1. Abhyankar S, Gilliland DG, Ferrara JLM (1993). Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplant 56:1518-1523.
2. Allen CM, Kapoor N (1993). Verruciform xanthoma in a bone marrow transplant recipient. Oral Surg Oral Med Oral Pathol 75:591-594.
3. Anasetti C, Martin PJ, Storb R, Appelbaum FR, Beatty PG, Davis J, et al. (1992). Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplant 54:844-851.
4. Antin JH, Ferrara JL (1992). Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964-2968.
5. Antin JH, Smith BR (1995). Bone marrow transplantation. In: Blood: Principles and practice of hematology. Handin RI, Lux SE, Stossel TP, editors. Philadelphia: J.B. Lippincott, pp. 2055-2103.
6. Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C, et al. (1991). Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78:2139-2149.
7. Atkinson K (1990). Treatment of extensive human chronic graft-vs-host disease. Hematology 12:681-690.
8. Atkinson K, Weller P, Ryman W, Biggs J (1986). PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1:227-236.
9. Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, et al. (1990). Risk factors for chronic graft-versus-host disease after HLA-identical sibling one marrow transplantation. Blood 75:2459-2464.
10. Barrett AP, Bilous M (1984). Oral patterns of acute and chronic graft-vs.-host disease. Arch Dermatol 120:1461-1465.
11. Bauer DJ, Hood AF, Horn TD (1993). Histologic comparison of autologous graft-versus-host reaction and cutaneous eruption of lymphocyte recovery. Arch Dermatol 1993:855-858.
12. Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ, et al. (1991). Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplant 51:443-447.
13. Berkowitz RJ, Strandjord S, Jones P, Hughes C, Barsetti J, Gordon EM (1987). Stomatologic complications of bone marrow transplantation in a pediatric population. Pediatr Dent 9:105-110.
14. Billingham RE (1966-1967). The biology of graft-versus-host reactions. Harvey Lect 62:21-78.
15. Birek C, Patterson B, Maximiw WC, Minden MD (1989). EBV and HSV infections in a patient who had undergone bone marrow transplantation: oral manifestations and diagnosis by in situ nucleic acid hybridization. Oral Surg Oral Med Oral Pathol 68:612-617.
16. Biaise D, Olive D, Hirn M, Viens P, Lafage M, Attal M, et al. (1991). Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow Transplant 8:105-111.
17. Bullorsky EO, Shanley CM, Stemmelin GR, Musso A, Rabinovich O, Ceresetto J, et al. (1993). Total lymphoid irradiation for treatment of drug resistant chronic GVHD. Bone Marrow Transplant 11:75-76.
18. Chambers MS, Lyzak WA, Martin JW, Lyzak JS, Toth BB (1995). Oral complications associated with aspergillosis in patients with a hematologic malignancy. Presentation and treatment. Oral Surg Oral Med Oral Pathol Oral Radial Endod 79:559-563.
19. Chaushu G, Itzkovitz-Chaushu S, Yefenof E, Slavin S, Or R, Garfunkel AA (1995). A longitudinal follow-up of salivary secretion in bone marrow transplant patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79:164-169.
20. Chosidow O, Bagot M, Vernant JP, Roujeau JC, Cordonnier C, Kuentz M, et al. (1992). Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases. J Am Acad Dermatol 26:49-55.
21. Clark JG, Schwartz DA, Flournoy N, Sullivan KM, Crawford SW, Thomas ED (1987). Risk factors for airflow obstruction in recipients of bone marrow transplants. Ann Intern Med 107:648-656.
22. Curtis JW Jr, Caughman GB (1994). An apparent unusual relationship between rampant caries and the oral mucosal manifestations of chronic graft-versus-host disease. Oral Surg Oral Med Oral Pathol 78:267-272.
23. Darmstadt GL, Donnenberg AD, Vogelsang GB, Farmer ER, Horn TD (1992). Clinical, laboratory, and histopathologic indicators of the development of progressive acute graft-versus-host disease. J Invest Dermatol 99:397-402.
24. Deeg HJ, Erickson K, Sullivan KM, Storb R (1988). Photoinactivation of lymphohemopoietic cells: studies in transfusion medicine and bone marrow transplantation. Blood Cells 18:151-162.
25. Dens F, Boogaerts M, Boute P, Declerck D, Demuynck H, Vinckier F (1996). Caries-related salivary microorganisms and salivary flow rate in bone marrow recipients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81:38-43.
26. Doney KC, Weiden PL, Storb R, Thomas ED (1981). Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplant 31:141-143.
27. Doney KC, Storb R, Beach K, Anasetti C, Deeg HJ, Hansen JA, et al. (1995). A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. Transplant 60:55-58.
28. Dreizen S, McCredie KB, Dicke KA, Zander AR, Peters LJ (1979). Oral complications of bone marrow transplantation in adults with acute leukemia. Postgrad Med 66:187-196.
29. Drijkoningen M, DeWolf-Peeters C, Tricot G, Degreef H, Desmet V (1988). Drug-induced skin reactions and acute cutaneous graft-versus-host reaction: a comparative immunohistochemical study. Blut 56:69-73.
30. Eppinger T, Ehninger G, Steinert M, Niethammer D, Dopfer R (1990). 8-methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplant 50:807-811.
31. Epstein JB, Reece DE (1994). Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 13:81-86.
32. Epstein JB, Sherlock CH, Wolber RA (1993). Hairy leukoplakia after bone marrow transplantation. Oral Surg Oral Med Oral Pathol 75:690-695.
33. Ferrara JLM, Deeg HJ (1991). Graft-versus-host disease. N Engl J Med 324:667-674.
34. Fischer A, Blanche S, Bidois JL, Bordigoni P, Gamier JL, Niaudet P, et al. (1991). Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndromes following bone marrow and organ transplantation. N Engl J Med 324:1451-1456.
35. Fujii H, Ohashi M, Nagura H (1988). Immunohistochemical analysis of oral lichen-planus-like eruption in graft-versus-host disease after allogeneic bone marrow transplantation. Am J Clin Pathol 89:177-186.
36. Fujii H, Hiketa T, Matsumoto Y, Chashi M, Miyamura Y, Tanimoto M, et al. (1992). Clinical characteristics of chronic cutaneous graft-versus-host disease in Japanese leukemia patients after bone marrow transplantation: low incidence and mild manifestations of skin lesions. Bone Marrow Transplant 10:331-335.
37. Fujiwara K, Sakaguchi N, Watanabe T (1991). Sialoadenitis in experimental graft-versus-host disease. An animal model of Sjögren's syndrome. Lab Invest 65:710-718.
38. Gaspari AA, Cheng SF, DiPersio JF, Rowe JM (1995). Roquinimex-induced graft-versus-host reaction after autologous bone marrow transplantation. J Am Acad Dermatol 33:711-717.
39. Gatti RA, Allen HJ, Meuwissen HD, Hong R, Good RA (1968). Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2:1366-1369.
40. Gehrke G, Schmelzle R, Meyle J, Kruger U (1986). Granuloma pyogenicum bei einem Patienten mit Erythroleukamie nach Knockenmarktransplantation. Dtsch Zahnärtzl Z 41:434-436.
41. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, et al. (1995). CD8-depleted donor lymphocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 11:4337-4343.
42. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. (1974). Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplant 18:295-304.
43. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, et al. (1988). Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806-814.
44. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, et al. (1990). Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 75:1606-1614.
45. Gratwhol AA, Moutsopoulos HM, Chused TM, Akizuki M, Wolf RO, Sweet JB, et al. (1977). Sjogren-type syndrome after allogeneic bone marrow transplantation. Ann Intern Med 87:703-706.
46. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, et al. (1991). Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525-1533.
47. Gryn J, Crilley P (1990). Tretinoin for the treatment of cutaneous graft-versus-host disease. Bone Marrow Transplant 5:279-280.
48. Heimdahl A, Johnson G, Danielsson KH, Lonnqvist B, Sundelin P, Ringden O (1985). Oral condition of patients with leukemia and severe aplastic anemia. Oral Surg Oral Med Oral Pathol 60:498-504.
49. Heney D, Norfolk DR, Wheeldon J, Bailey CC, Lewis IJ, Barnard DL (1991). Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol 78:23-27.
50. Herve P, Wijdenes J, Bergerat JP, Bordigoni P, Milpied N, Cahn JY, et al. (1990). Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 75:1017-1023.
51. Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, et al. (1992). Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79:3362-3368.
52. Hess AD, Fischer AC (1989). Immune mechanisms in cyclosporin-induced syngeneic graft-versus-host disease. Transplant 48:895-900.
53. Hiroki A, Nakamura S, Shinohara M, Oka M (1994). Significance of oral examination in chronic graft-versus-host disease. J Oral Pathol Med 23:209-215.
54. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, et al. (1990). Increased serum levels of tumor necrosis factor-alpha precede major complications of bone marrow transplantation. Blood 75:1011-1016.
55. Hood A, Vogelsang G, Black C, Farmer ER, Santos GW (1987). Acute graft-versus-host disease following autologous and syngeneic bone marrow transplantation. Arch Dermatol 123:745-750.
56. Horn TD, Bauer DJ, Vogelsang GB, Hess AD (1994). Reappraisal of histologic features of the acute cutaneous graft-versus-host reaction based on an allogeneic rodent model. J Invest Dermatol 103:206-210.
57. Hsiao M, Schubert MM, Thornquist M (1988). Oral manifestations of acute graft-versus-host disease (A-GVHD) following marrow transplantation (MTx) (abstract). J Dent Res 67(Spec Iss):202.
58. Izutsu KT, Sullivan KM, Schubert MM, Truelove EL, Shulman HM, Sale GE, et al. (1983a). Disordered salivary immunoglobulin secretion and sodium transport in human graft-versus-host disease. Transplant 35:441-446.
59. Izutsu KT, Schubert MM, Truelove EL, Shulman HM, Sale GE, Morton TH, et al. (1983b). The predictive value of elevated labial saliva sodium concentration: its relation to labial gland pathology in bone marrow transplant recipients. Hum-Pathol 13:29-35.
60. Izutsu KT, Menard TW, Schubert MM, Ensign WY, Sullivan K, Truelove EL, et al. (1985). Graft versus host disease-related secretory immunoglobulin A deficiency in bone marrow transplant recipients. Findings in labial saliva. Lab Invest 52:292-297.
61. Janin-Mercier A, Saurat JH, Bourges M, Sohier J, Jean LD, Gluckman E (1981). The lichen planus like and sclerotic phases of the graft versus host disease in man. Acta Derm Venereal (Stockh) 61:187-193.
62. Janin-Mercier A, Devergie A, Arrago JP, Brocheriou C, Lemarchand-Venencie F, Rain JD, et al. (1987). Systemic evaluation of Sjogren-like syndrome after bone marrow transplantation in man. Transplant 43:677-679.
63. Jones LR, Toth BB, Keene HJ (1992). Effects of total body irradiation on salivary gland function and caries-associated oral microflora in bone marrow transplant patients. Oral Surg Oral Med Oral Pathol 73:670-676.
64. Kier P, Penner E, Bakos S, Kalhs P, Lechner K, Volc-Platzer B, et al. (1990). Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies. Bone Marrow Transplant 6:93-96.
65. Kolbinson DK, Schubert MM, Flournoy N, Truelove EL (1988). Early oral changes following bone marrow transplantation. Oral Surg Oral Med Oral Pathol 66:130-138.
66. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P (1990). T-lymphocyte antigen interactions in transplant rejection. N Engl J Med 322:510-517.
67. Lawley TJ, Peck GL, Moutsopoulos HM, Gratwohl AA, Deisseroth AB (1977). Scleroderma, Sjögren's-like syndrome, and chronic graft-versus-host disease. Ann Intern Med 87:707-709.
68. Lee L, Miller PA, Maxymiw WG, Messner HA, Rotstein LE (1994). Intraoral pyogenic granuloma after allogenic bone marrow transplant. Oral Surg Oral Med Oral Pathol 78:607-610.
69. Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED (1974). Histopathology of graft-versus-host reaction (GvHR) in human recipients of marrow from HLA-matched sibling donors. Transplant Proc 6:367-371.
70. LeVeque FG, Ratanatharathorn V, Dan ME, Orville B, Coleman DN, Turner S (1994). Oral cytomegalovirus infection in an unrelated bone marrow transplantation with possible mediation by graft-versus-host disease and the use of cyclosporin-A. Oral Surg Oral Med Oral Pathol 77:248-253.
71. Lister J, Messner H, Keystone E, Miller R, Fritzler MJ (1987). Autoantibody analysis of patients with graft versus host disease. J Clin Lab Immunol 24:19-23.
72. Lloid ME, Schubert MM, Myerson D, Bowden R, Meyers JD, Hackman RC (1994). Cytomegalovirus infection of the tongue following marrow transplantation. Bone Marrow Transplant 14:99-104.
73. Lortan JE, Rochfort NC, El-Tumi M, Vellodi A (1992). Autoantibodies after bone marrow transplantation in children with genetic disorders: relation to chronic graft-versus-host disease. Bone Marrow Transplant 9:325-330.
74. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, et al. (1995). Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261-1268.
75. Martin P, Clift R, Fisher L, Buckner CD, Hansen JA, Appelbaum FR, et al. (1988). HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. Blood 72:1978-1984.
76. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. (1990). A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76:1464-1472.
77. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB, et al. (1991). A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 77:1821-1828.
78. Masaoka T, Shibata H, Kakishita E, Kanamaru A, Takemoto Y, Moriyama Y (1991). Phase II study of FK 506 for allogeneic bone marrow transplantation. Transplant Proc 23:3228-3231.
79. Mattsson T, Heimdahl A, Dahllöf G, Lonnquist B, Ringdén O (1992a). Oral and nutritional status in allogeneic marrow recipients treated with T-cell depletion or cyclosporine combined with methotrexate to prevent graft-versus-host disease. Oral Surg Oral Med Oral Pathol 74:34-40.
80. Mattsson T, Sundqvist KG, Heimdahl A, Dahllöf G, Ljungman P, Ringdén O (1992b). A comparative immunological analysis of the oral mucosa in chronic graft-versus-host disease and oral lichen planus. Arch Oral Biol 37:539-547.
81. McCarthy PL Jr, Abhyankar S, Neben G, Newan G, Sieff C, Thompson RC, et al. (1991). Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78:1915-1918.
82. McCullough J, Hansen J, Perkins H, Stroncek D, Bartsch G (1989). The National Marrow Donor Program: how it works, accomplishments to date. Oncol 3:63-68.
83. McDonald GB, Sullivan KM, Schuffler MD, Shulman HM, Thomas ED (1981). Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterol 80:914-921.
84. Medina JE, Frame R, Toth B, Nguyen L, Luna MH (1984). Head and neck manifestations of the chronic graft vs. host disease. Laryngoscope 94:1145-1151.
85. Nagler R, Marmary Y, -Krausz Y, Chisin R, Markitziu A, Nagler A (1996). Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 17:219-224.
86. Nakhleh RE, Miller W, Snover DC (1989). Significance of mucosal vs. salivary gland changes in lip biopsies in the diagnosis of chronic graft-vs-host disease. Arch Pathol Lab Med 113:932-934.
87. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, et al. (1992). Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 80:1838-1845.
88. Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, et al. (1995). Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single center study. Blood 85:3746-3753.
89. Norhagen G, Engström PE, Björkstrand B, Hammarström L, Smith CI, Ringdén O (1994). Salivary and serum immunoglobulins in recipients of transplanted allogeneic and autologous bone marrow. Bone Marrow Transplant 14:229-234.
90. Owsianowski M, Gollnick H, Siegert W, Schwerdtfeter R, Orfanos CE (1994). Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant 14:845-848.
91. Piguet PF, Grau GE, Allet B, Vassalli P (1987). Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 166:1280-1289.
92. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH (1994). Induction of graft-versus-host disease as immunotherapy for relapsed chronic muyeloid leukemia. N Engl J Med 330:100-106.
93. Pottage JC Jr, Kessler HA (1995). Herpes simplex virus resistance to acyclovir: clinical relevance. Infect Agents Dis 4:115-124.
94. Ringden O, Kersey JH (1992). Prevention and therapy of graft-versus-host disease. Report from a workshop. Bone Marrow Transplant 10(Suppl):22-24.
95. Rodu B, Gockerman JP (1983). Oral manifestations of the chronic graft-v-host reaction. J Am Med Assoc 249:504-507.
96. Rossetti F, Zulian F, Dall'Amico R, Messina C, Montini G, Zacchello F (1995). Extracorporeal photochemotherapy as single therapy for extensive, cutaneous, chronic graft-versus-host disease. Transplant 59:149-151.
97. Rouquette-Gally AM, Boyeldieu D, Gluckman E, Abuaf N, Combrisson A (1987). Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjogren syndrome and scleroderma. Br J Haematol 66:45-47.
98. Sale GE, Shulman HM, Schubert MM, Sullivan KM, Kopecky KJ, Hackman RC, et al. (1981). Oral and ophthalmic pathology of graft versus host disease in man: predictive value of the lip biopsy. Hum Pathol 12:1022-1030.
99. Sale GE, Shulman HM, Galluci BB, Thomas ED (1985). Young rete ridge keratinocytes are preferred targets in cutaneous graft-vs.-host disease. Am J Pathol 118:278-287.
100. Sale GE, Anderson P, Browne M, Myerson D (1992). Evidence of cytotoxic T-cell destruction of epidermal cells in human graft-vs-host disease. Immunohistology with monoclonal antibody TIA-1. Arch Pathol Lab Med 116:622-625.
101. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS (1981). A randomized, double-blind controlled trial in bone-marrow-transplant recipients. N Engl J Med 305:63-67.
102. Saurat JH (1981). Cutaneous manifestations of graft-versus-host disease. Int J Dermatol 4:249-256.
103. Saurat JH (1991). Retinoids for cutaneous graft-versus-host disease, topical or systemic? (letter). Bone Marrow Transplant 7:249.
104. Saurat JH, Gluckman E, Bussel A, Didierjan L, Puissant A (1975). The lichen planus-like eruption after bone marrow transplantation. Br J Dermatol 93:675-681.
105. Schubert MM, Sullivan KM (1990). Recognition, incidence, and management of oral graft-versus-host disease. NCI Monogr 9:135-143.
106. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson DE, Flournoy N, et al. (1984). Oral manifestations of chronic graft-v-host disease. Arch Intern Med 144:1591-1595.
107. Schubert MM, Peterson DE, Flournoy N, Meyers JD, Truelove L (1990a). Oral and pharyngeal herpes simplex virus infection after allogenic bone marrow transplantation: analysis of factors associated with infection. Oral Sura Oral Med Oral Pathol 70:286-293.
108. Schubert MA, Sullivan KM, Schubert MM, Nims J, Hansen M, Sanders JE, et al. (1990b). Gynecological abnormalities following allogeneic bone marrow transplantation. Bone Marrow Transplant 5:425-430.
109. Shulman HM, Sale GE, Lerner KG (1978). Chronic cutaneous graft-versus-host disease in man. Am J Pathol 91:545-570.
110. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. (1980). Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204-217.
111. Singhal S, Mehta J, Rattenbury H, Treleaven J, Powles R (1995). Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease. Blood 85:1147-1148.
112. Socie G, Devergie A, Cosset JM, Pierga JY, Esperou H, Girinski T, et al. (1990). Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplant 49:657-658.
113. Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, et al. (1992). Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79:517-526.
114. Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, et al. (1983). Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 308:302-307.
115. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, et al. (1989). Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73:1729-1734.
116. Sullivan KM (1986). Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 4:42-93.
117. Sullivan KM, Parkman R (1983). The pathophysiology and treatment of graft-versus-host disease. Clin Haematol 12:775-789.
118. Sullivan KM, Shulman HM, Storb R, Weiden PL, McDonald RP, Witherspoon RP, et al. (1981). Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 57:267-276.
119. Sullivan K, Weiden P, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. (1989). Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720-1728.
120. Sullivan KM, Siadak MF, Witherspoon RP (1990). Cyclosporine treatment of chronic graft-versus-host disease following allogeneic bone marrow transplantation. Transplant Proc 22:1336-1338.
121. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. (1991a). Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Sem Hematol 28:250-259.
122. Sullivan KM, Kopecky KJ, Buckner CD, Storb R (1991b). Intravenous IgG to prevent graft-versus-host disease after bone marrow transplantation (letter). N Engl J Med 324:631-633.
123. Symington FW, Pepe MS, Chen AB, Deliganis A (1990). Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans. Transplant 50:518-521.
124. Thomas ED, Lochte HL, Cannon JH, Sahler OD, Ferrebee JW (1959). Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 38:1709-1716.
125. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. (1975). Bone-marrow transplantation. N Engl J Med 292:832-843, 895-902.
126. Truelove EL, Izutsu KT, Schubert MM (1982). Salivary lysozyme levels are increased in bone marrow transplant (BMT) recipients (abstract). J Dent Res 68:223.
127. Tzakis AG, Abu-Elmagd K, Fung JJ, Bloom EJ, Nour B, Greif F, et al. (1991). FK 506 rescue in chronic graft-versus-host disease after bone marrow transplantation. Transplant Proc 23:3225-3227.
128. Unanue ER, Allen PM (1987). The basis for the immunoregulatory role of macrophages and other accessory cells. Science 236:551-557.
129. Van-Joost T, Vuzevski VD, Ten Kate F, Hagenbeek A (1987). Localized oral and perioral lesions in chronic graft-versus-host disease (letter). J Am Acad Dermatol 16(1 Pt 1):138-139.
130. Vogelsang GB, Hess AD, Santos GW (1988). Acute graft-versus-host disease: clinical characteristics in the cyclosporine era. Med 67:163-174.
131. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, et al. (1992). Thalidomide for the treatment of chronic graft versus host disease. N Engl J Med 326:1055-1058.
132. Volc-Platzer B, Honigsmann H, Hinterberger W, Wolff K (1990). Photochemotherapy improves chronic cutaneous graft-versus-host disease. J Am Acad Dermatol 23:220-228.
133. Vossen JM, Heidt PJ (1990). Gnotobiotic measures for the prevention of acute graft-vs-host disease. Hematol 12:403-413.
134. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED (1981). Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529-1533.
135. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N, et al. (1991). Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplant 51:1197-1203.
136. Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin LS, et al. (1989). Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74:1428-1435.
137. Woo S, Sonis ST, Monopoli MM, Sonis AL (1993). A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 72:1612-1617.